Blog
About

7
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Alopecia areata (AA) is an autoimmune disease characterized by hair loss mediated by CD8(+) T cells. There are no reliably effective therapies for AA. Based on recent developments in the understanding of the pathomechanism of AA, JAK inhibitors appear to be a therapeutic option; however, their efficacy for the treatment of AA has not been systematically examined.

          Related collections

          Author and article information

          Journal
          JCI Insight
          JCI insight
          American Society for Clinical Investigation
          2379-3708
          2379-3708
          Sep 22 2016
          : 1
          : 15
          Affiliations
          [1 ] Program in Epithelial Biology and Department of Dermatology, Stanford University School of Medicine, Stanford, California, USA.
          [2 ] Department of Dermatology,; Department of Pediatrics, and.
          [3 ] Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut, USA.
          [4 ] Department of Dermatology,; Department of Systems Biology, and.
          [5 ] Department of Dermatology.
          [6 ] Department of Dermatology,; Department of Genetics and Development, Columbia University, New York, New York, USA.
          Article
          89776
          10.1172/jci.insight.89776
          5033755
          27699252

          Comments

          Comment on this article